Embedding stakeholder preferences in setting priorities for health research: Using a discrete choice experiment to develop a multi-criteria tool for evaluating research proposals.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 21 09 2022
accepted: 19 11 2023
medline: 7 12 2023
pubmed: 7 12 2023
entrez: 7 12 2023
Statut: epublish

Résumé

We determined weights for a multi-criteria tool for assessing the relative merits of clinical-trial research proposals, and investigated whether the weights vary across relevant stakeholder groups. A cross-sectional, adaptive discrete choice experiment using 1000minds online software was administered to consumers, researchers and funders affiliated with the Australian Clinical Trials Alliance (ACTA). We identified weights for four criteria-Appropriateness, Significance, Relevance, Feasibility-and their levels, representing their relative importance, so that research proposals can be scored between 0% (nil or very low merit) and 100% (very high merit). From 220 complete survey responses, the most important criterion was Appropriateness (adjusted for differences between stakeholder groups, mean weight 28.9%) and the least important was Feasibility (adjusted mean weight 19.5%). Consumers tended to weight Relevance more highly (2.7% points difference) and Feasibility less highly (3.1% points difference) than researchers. The research or grant writing experience of researchers or consumers was not associated with the weights. A multi-criteria tool for evaluating research proposals that reflects stakeholders' preferences was created. The tool can be used to assess the relative merits of clinical trial research proposals and rank them, to help identify the best proposals for funding.

Identifiants

pubmed: 38060475
doi: 10.1371/journal.pone.0295304
pii: PONE-D-22-25100
pmc: PMC10703277
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0295304

Informations de copyright

Copyright: © 2023 Taylor et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Soc Sci Med. 2020 Feb;246:112707
pubmed: 31945596
Trials. 2022 Dec 12;23(1):1000
pubmed: 36510214
Int J Technol Assess Health Care. 2006 Summer;22(3):379-87
pubmed: 16984067
Lancet. 2009 Jul 4;374(9683):86-9
pubmed: 19525005
Lancet. 2014 Mar 29;383(9923):1125-6
pubmed: 24679626
CMAJ Open. 2021 May 21;9(2):E522-E528
pubmed: 34021009
Eur J Phys Rehabil Med. 2019 Jun;55(3):322-330
pubmed: 30947492
BMJ Open. 2018 Dec 22;8(12):e026207
pubmed: 30580278

Auteurs

William J Taylor (WJ)

Department of Medicine, University of Otago, Wellington, New Zealand.
Hutt Valley District Health Board, Lower Hutt, New Zealand.
Tairawhiti District Health Board, Gisborne, New Zealand.

Haitham Tuffaha (H)

Centre for the Business and Economics of Health, University of Queensland, Brisbane, Australia.

Carmel M Hawley (CM)

Australasian Kidney Trials Network (AKTN), Brisbane, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.
Translational Research Institute, Brisbane, Queensland, Australia.

Philip Peyton (P)

Australia and New Zealand College of Anaesthetists Clinical Trials Network, Melbourne, Australia.

Alisa M Higgins (AM)

Australia and New Zealand Intensive Care-Research Centre, Monash University, Melbourne, Australia.

Paul A Scuffham (PA)

Menzies Health Institute Queensland, Brisbane, Australia.

Fiona Nemeh (F)

Australian Clinical Trials Alliance, Melbourne, Australia.

Anitha Balagurunathan (A)

Australian Clinical Trials Alliance, Melbourne, Australia.

Paul Hansen (P)

Department of Economics, University of Otago, Dunedin, New Zealand.

Angela Jacques (A)

Institute for Health Research, The University of Notre Dame, Freemantle, Australia.

Rachael L Morton (RL)

NHMRC Clinical Trials Centre, Sydney, Australia.

Classifications MeSH